• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:30:55 PM ET
    $IMMU
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IMMU alert in real time by email
    SC 13G/A 1 b021221a.htm SCHEDULE 13G (AMENDMENT #1)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    (Name of Issuer)
    Immunomedics, Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.01 Per Share

    (CUSIP Number)

    452907108
    (Date of Event Which Requires Filing of this Statement)
    December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 452907108
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     

    CUSIP No. 452907108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions)  CO
     

    CUSIP No. 452907108
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     

    CUSIP No. 452907108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     


    Item 1(a) Name of issuer:
    Immunomedics, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    300 The American Road, Morris Plains, New Jersey 07950
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.01 per
    share (“Shares”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
    respect to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Cubist Systematic Strategies.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT
    06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr.
    Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.01 Per Share
    2(e) CUSIP Number:
    452907108

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2020:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0 
    (iii) Sole power to dispose or to direct the disposition of: 0 
    (iv) Shared power to dispose or to direct the disposition of: 0

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0 
    (iv) Shared power to dispose or to direct the disposition of: 0

    4. Steven A. Cohen
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0
    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by certain investment funds it manages.
    Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.
    Pursuant to an investment management agreement, Cubist Systematic Strategies
    maintains investment and voting power with respect to the securities held by certain
    investment funds it manages. Mr. Cohen controls each of Point72 Asset Management,
    Point72 Capital Advisors Inc., and Cubist Systematic Strategies. Each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr.
    Cohen disclaims beneficial ownership of any of the securities covered by this
    statement.
    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to
    above were not acquired and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired and are not held in
    connection with or as a participant in any transaction having that purpose or effect, other than
    activities solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 16, 2021

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person



    Get the next $IMMU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMMU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMMU
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

      WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

      12/1/20 7:30:00 AM ET
      $IMMU
      $URGN
      $FREQ
      $JNJ
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMMU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

      WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

      12/1/20 7:30:00 AM ET
      $IMMU
      $URGN
      $FREQ
      $JNJ
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMMU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - IMMUNOMEDICS INC (0000722830) (Subject)

      2/16/21 3:30:55 PM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IMMU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-58) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 11/22/2024. Application Category: BLA, Application Number: 761115, Application Classification:

      11/25/24 4:48:58 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-35) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 02/03/2023. Application Category: BLA, Application Number: 761115, Application Classification:

      2/3/23 11:40:04 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-23) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/03/2022. Application Category: BLA, Application Number: 761115, Application Classification:

      6/6/22 4:34:38 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care